Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

Contact Us

Search

Pneumococcal Disease

Vaccines

Vaccines Today—March 27, 2026

This week’s Vaccines and Infectious Disease update highlights clinical trial…

Vaccines

Vaccines Today—March 6, 2026

This weekly update in vaccines highlights key developments across regulatory…

Vaccines_News

Vaccines Video Recap—December 12, 2025

This biweekly Vaccines video recap highlights covers regulatory/policy…

Vaccines

Vaccines Today—December 12, 2025

This week’s vaccines update highlights key vaccine and immunology developments,…

Vaccines

Vaccines Weekly Update - September 19th 2025

Vaccine Research Update: PCV21 in Children, COVID-19 for Immunocompromised,…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital Trends
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Healthcare and Pharma Trends
Rare Disease News
Health Mobile Apps Reports
Neuroscience News
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Lucid Diligence Brief: STORM Therapeutics $56 million Series C for Phase II in Sarcoma
Respiratory Today—April 17, 2026
Vaccines Today—April 17, 2026
Public Health Today—April 17, 2026
Lucid Diligence Brief: Vir Biotechnology $1.37B collaboration with Astellas

Tags

AACR 2025 AHA Go Red ANAVEX 3-71 Avenzo Therapeutics Bofanglutide bone marrow failure chronic spontaneous urticaria dual incretins endocrine resistance endoluminal robotics enzyme replacement Fertility issues FreeStyle Libre 3 gestational trophoblastic tumors GLP-1 combinations graphene devices Hippo pathway IL-6 Inherited retinal diseases Innate Pharma Lassa fever mitral TEER monash Non-muscle invasive bladder cancer Osqay Partners Health Management pharma R&D plasma-derived therapies Rare endocrine disorders Recor Medical Rocket Pharmaceuticals Secukinumab self.co sexual health Sweden SWOG syndax pharmaceuticals Taho Pharmaceuticals talkspace Theramex TSHA-102 Vitiligo vre infection Wandercraft Zealand Pharma

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Lucid Diligence Brief: STORM Therapeutics $56 million Series C for Phase II in Sarcoma
Respiratory Today—April 17, 2026
Vaccines Today—April 17, 2026
Public Health Today—April 17, 2026
Lucid Diligence Brief: Vir Biotechnology $1.37B collaboration with Astellas

TAGS

AACR 2025 AHA Go Red ANAVEX 3-71 Avenzo Therapeutics Bofanglutide bone marrow failure chronic spontaneous urticaria dual incretins endocrine resistance endoluminal robotics enzyme replacement Fertility issues FreeStyle Libre 3 gestational trophoblastic tumors GLP-1 combinations graphene devices Hippo pathway IL-6 Inherited retinal diseases Innate Pharma Lassa fever mitral TEER monash Non-muscle invasive bladder cancer Osqay Partners Health Management pharma R&D plasma-derived therapies Rare endocrine disorders Recor Medical Rocket Pharmaceuticals Secukinumab self.co sexual health Sweden SWOG syndax pharmaceuticals Taho Pharmaceuticals talkspace Theramex TSHA-102 Vitiligo vre infection Wandercraft Zealand Pharma

Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy